Revvity (RVTY) reported Q1 adjusted earnings Monday of $1.01 per diluted share, up from $0.98 a year earlier.
Analysts polled by FactSet expected $0.95.
Revenue for the quarter ended March 31 was $664.8 million, up from $649.9 million a year earlier.
Analysts surveyed by FactSet expected $661.0 million.
For 2025, the biopharmaceutical company maintained its adjusted EPS guidance of $4.90 to $5.00 while raising its revenue forecast to $2.83 billion to $2.87 billion, up from its previous projection of $2.80 billion to $2.85 billion.
Analysts polled by FactSet expect non-GAAP EPS of $4.92 on revenue of $2.83 billion.
Shares of the company were up nearly 5% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.